XLO Earnings

Quarterly EPS
$-3.08
Q3 2024
$-2.82
Q4 2024
$-2.49
Q1 2025
$-2.30
Q2 2025
$-1.54
Q3 2025
$0.00
Q4 2025
$-0.58
Q1 2026
$-0.33
Q2 2026
Latest Revenue18.7M
Latest Net Income-6373000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.3318.7M-6373000+131.2%+85.7%
Q1 2026-$0.5812.6M-9529000+331.7%+76.7%
Q4 202513.7M10.4M+693.9%
Q3 2025-$1.5419.1M-16287000+742.5%+50.0%
Q2 2025-$2.308.1M-15844000+243.0%+31.5%
Q1 2025-$2.492.9M-13265000+71.3%
Q4 2024-$2.821.7M-13093000+68.6%
Q3 2024-$3.082.3M-14020000+63.9%
Q2 2024-$3.362.4M-13925000
Q1 2024-$8.680-17203000
Q4 2023-$8.970-17655000
Q3 2023-$8.540-16748000
Xilio Therapeutics (XLO) — Earnings